Age: 63.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Blister, Herpes zoster, Inappropriate schedule of product administration, Vaccination failure
Clinical narrative: mild case of shingles with 4 vesicles; suspected vaccination failure; received her SHINGRIX dose 1 06/20/2018 and dose 2 03/29/2019; mild case of shingles; shingles vesicles above and below her transverse C-section scar it was fairly mild; shingles experiences with vesicles; This serious case was reported by a nurse via call center representative and described the occurrence of vaccination failure in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 29-MAR-2019, the patient received the 2nd dose of Shingrix. On 20-JUN-2018, the patient received the 1st dose of Shingrix. On 29-MAR-2019, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received her SHINGRIX dose 1 06/20/2018 and dose 2 03/29/2019). On 01-JUL-2022, the patient experienced vaccination failure (Verbatim: suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: mild case of shingles). On 30-MAY-2024, the patient experienced shingles (Verbatim: shingles vesicles above and below her transverse C-section scar it was fairly mild). On 24-SEP-2024, the patient experienced shingles (Verbatim: shingles experiences with vesicles). On 22-OCT-2024, the patient experienced shingles (Verbatim: mild case of shingles with 4 vesicles). The patient was treated with valaciclovir hydrochloride (Valtrex). In JUL-2022, the outcome of the shingles was resolved (duration 2 weeks).  In JUN-2024, the outcome of the shingles was resolved (duration 2 weeks).  In OCT-2024, the outcome of the shingles was resolved (duration 10 days). The outcome of the vaccination failure was not reported and the outcome of the shingles was resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the vaccination failure, shingles, shingles, shingles and shingles to be related to Shingrix and Shingrix.     The company considered the vaccination failure to be unrelated to Shingrix and Shingrix. It was unknown if the company considered the shingles, shingles, shingles and shingles to be related to Shingrix and Shingrix.   Additional Information: GSK Receipt Date: 05-DEC-2024 The patient was a Registered Nurse who received her 2 doses of Shingrix and on 1-JUL-2022 she experienced a mild case of shingles that lasted two weeks.  On 30-MAY-2024 she experienced shingles vesicles above and below her transverse C-section scar.  This was fairly mild and lasted about 2 weeks.  On 24-SEP-2024 she experienced what she described as the worst of her shingles experiences with vesicles on her left forearm, left abdomen below the breast, and right abdomen.  This episode lasted about 10 days.  On 1-OCT-2024 she began taking VALTREX 500 mg as a preventative. On 22-OCT-2024 she experienced a mild case of shingles with 4 vesicles on her left forearm and one on her right inner elbow.  She was taking the VALTREX at that time, and remained on VALTREX. The patient stated that she had photos of all of the outbreaks and would share them with GSK. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. This case was considered as suspected vaccination failure as details of laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingrix (dose 1) and Shingrix (dose 2).